Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest United States corporations. In 2024, the company was ranked 45th in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 138,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato. Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| JNJ | JOHNSON & JOHNSON | 2025-10-16 22:08:30 | 191.98 | -0.14 | -0.07 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | 0000200406 | JOHNSON & JOHNSON | US4781601046 | 549300GQXUV37X4D2C47 | 221024240 | NYSE | 2834 | Pharmaceutical Preparations | 1228 | NJ | ONE JOHNSON & JOHNSON PLZ | NEW BRUNSWICK | NJ | 08933 | UNITED STATES | US | 732-524-2455 | ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933 | ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933 | JOHNSON & JOHNSON ET AL | Pharmaceutical | 1886 | Joaquin Duato | 138,100 | https://www.jnj.com/ | 352,000,000,000 | 3,119,843,000 | 2,408,338,872 | Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest United States corporations. In 2024, the company was ranked 45th in the Forbes Global 2000. Johnson & Johnson has a global workforce of approximately 138,000 employees who are led by the company's current chairman and chief executive officer, Joaquin Duato. Johnson & Johnson is one of the world's most valuable companies and is one of only two U.S.-based companies that has a prime credit rating of AAA. | 2025-10-10 19:00:15 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 352,000,000,000 | -78,000,000,000 | -18.1395 | 2,407,616,693 | -1,150,535 | -0.0478 |
| 2023 | 430,000,000,000 | -42,000,000,000 | -8.8983 | 2,408,767,228 | -195,519,075 | -7.5076 |
| 2022 | 472,000,000,000 | 27,000,000,000 | 6.0674 | 2,604,286,303 | -24,981,855 | -0.9501 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| J. Duato | CEO, Chairman | 2024 | 1,600,000 | 0 | 10,787,159 | 3,981,050 | 320,160 | 24,302,360 |
| T. Schmid | EVP | 2024 | 896,308 | 0 | 3,012,514 | 1,392,200 | 4,051,929 | 11,862,938 |
| J. Duato | CEO, Chairman | 2023 | 1,584,615 | 0 | 11,182,143 | 4,378,500 | 241,992 | 28,397,240 |
| A. Mcevoy | EVP | 2023 | 1,059,231 | 0 | 4,015,750 | 1,261,500 | 47,665 | 9,403,150 |
| A. Mcevoy | EVP | 2022 | 984,615 | 0 | 3,935,021 | 890,250 | 44,308 | 7,390,161 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 138,100 |
| 2023 | 152,700 |
| 2022 | 141,700 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 88,821,000,000 | 85,159,000,000 | 94,943,000,000 |
| Cost Of Revenue | 27,471,000,000 | 26,553,000,000 | 31,089,000,000 |
| Gross Profit | 61,350,000,000 | 58,606,000,000 | 63,854,000,000 |
| Research And Development Expenses | 1,841,000,000 | 483,000,000 | 14,603,000,000 |
| General And Administrative Expenses | 22,869,000,000 | 21,512,000,000 | 24,765,000,000 |
| Operating Expenses | — | — | — |
| Operating Income | — | — | — |
| Net Income | 14,066,000,000 | 35,153,000,000 | 17,941,000,000 |
| Earnings Per Share Basic | 5.84 | 13.88 | 6.83 |
| Earnings Per Share Diluted | 5.79 | 13.72 | 6.73 |
| Weighted Average Shares Outstanding Basic | 2,407,300,000 | 2,533,500,000 | 2,625,200,000 |
| Weighted Average Shares Outstanding Diluted | 2,429,400,000 | 2,560,400,000 | 2,663,900,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 24,105,000,000 | 21,859,000,000 | 14,127,000,000 |
| Marketable Securities Current | 417,000,000 | 1,068,000,000 | 9,392,000,000 |
| Accounts Receivable | 14,842,000,000 | 14,873,000,000 | 16,160,000,000 |
| Inventories | 12,444,000,000 | 11,181,000,000 | 12,483,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 55,893,000,000 | 53,495,000,000 | 55,294,000,000 |
| Marketable Securities Non Current | 451,000,000 | 4,473,000,000 | 576,000,000 |
| Property Plant And Equipment | 20,518,000,000 | 19,898,000,000 | 19,803,000,000 |
| Other Assets Non Current | 11,414,000,000 | 14,153,000,000 | 9,602,000,000 |
| Total Assets Non Current | 70,670,000,000 | 54,832,000,000 | 66,283,000,000 |
| Total Assets | 180,104,000,000 | 167,558,000,000 | 187,378,000,000 |
| Accounts Payable | 10,311,000,000 | 9,632,000,000 | 11,703,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 6,000,000,000 | 3,500,000,000 | 12,800,000,000 |
| Other Liabilities Current | 8,549,000,000 | 10,212,000,000 | 11,456,000,000 |
| Total Liabilities Current | 50,321,000,000 | 46,282,000,000 | 55,802,000,000 |
| Long Term Debt | 32,400,000,000 | 27,350,000,000 | 28,439,000,000 |
| Other Liabilities Non Current | 17,549,000,000 | 13,398,000,000 | 10,437,000,000 |
| Total Liabilities Non Current | 58,293,000,000 | 52,502,000,000 | 54,772,000,000 |
| Total Liabilities | 108,614,000,000 | 98,784,000,000 | 110,574,000,000 |
| Common Stock | 3,120,000,000 | 3,120,000,000 | 3,120,000,000 |
| Retained Earnings | 155,791,000,000 | 153,843,000,000 | 128,345,000,000 |
| Accumulated Other Comprehensive Income | -11,741,000,000 | -12,527,000,000 | -12,967,000,000 |
| Total Shareholders Equity | 71,490,000,000 | 68,774,000,000 | 76,804,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 7,339,000,000 | 7,486,000,000 | 6,970,000,000 |
| Share Based Compensation Expense | 1,176,000,000 | 1,162,000,000 | 1,138,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 406,000,000 | 624,000,000 | 1,290,000,000 |
| Change In Inventories | 1,128,000,000 | 1,323,000,000 | 2,527,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -1,717,000,000 | 3,480,000,000 | -687,000,000 |
| Change In Accounts Payable | 1,621,000,000 | 2,346,000,000 | 1,098,000,000 |
| Change In Other Liabilities | 33,000,000 | 5,588,000,000 | -1,979,000,000 |
| Cash From Operating Activities | 24,266,000,000 | 22,791,000,000 | 21,194,000,000 |
| Purchases Of Marketable Securities | 1,726,000,000 | 10,906,000,000 | 32,384,000,000 |
| Sales Of Marketable Securities | 2,462,000,000 | 19,390,000,000 | 41,609,000,000 |
| Acquisition Of Property Plant And Equipment | 4,424,000,000 | 4,543,000,000 | 4,009,000,000 |
| Acquisition Of Business | 15,146,000,000 | 0 | 17,652,000,000 |
| Other Investing Activities | 174,000,000 | -12,000,000 | 229,000,000 |
| Cash From Investing Activities | -18,599,000,000 | 878,000,000 | -12,371,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 11,823,000,000 | 11,770,000,000 | 11,682,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 2,432,000,000 | 5,054,000,000 | 6,035,000,000 |
| Issuance Of Long Term Debt | 6,660,000,000 | 0 | 2,000,000 |
| Repayment Of Long Term Debt | 1,453,000,000 | 1,551,000,000 | 2,134,000,000 |
| Other Financing Activities | -38,000,000 | -269,000,000 | 93,000,000 |
| Cash From Financing Activities | -3,132,000,000 | -15,825,000,000 | -8,871,000,000 |
| Change In Cash | 2,246,000,000 | 7,732,000,000 | -360,000,000 |
| Cash At End Of Period | 24,105,000,000 | 21,859,000,000 | 14,127,000,000 |
| Income Taxes Paid | 6,714,000,000 | 8,574,000,000 | 5,223,000,000 |
| Interest Paid | 1,990,000,000 | 1,836,000,000 | 982,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 5.84 | 13.88 | 6.83 |
| Price To Earnings Ratio | 24.5445 | 11.2925 | 25.8638 |
| Earnings Growth Rate | -57.9251 | 103.2211 | -13.8714 |
| Price Earnings To Growth Ratio | -0.4237 | 0.1094 | -1.8645 |
| Book Value Per Share | 29.6972 | 27.1458 | 29.2564 |
| Price To Book Ratio | 4.8267 | 5.774 | 6.038 |
| Ebitda | 28,874,000,000 | 51,985,000,000 | 30,410,000,000 |
| Enterprise Value | 359,357,382,000 | 406,091,790,000 | 490,853,580,000 |
| Dividend Yield | 0.0343 | 0.0296 | 0.0252 |
| Dividend Payout Ratio | 0.8405 | 0.3348 | 0.6511 |
| Debt To Equity Ratio | 0.5371 | 0.4486 | 0.5369 |
| Capital Expenditures | 7,959,000,000 | 7,581,000,000 | 7,811,000,000 |
| Free Cash Flow | 16,307,000,000 | 15,210,000,000 | 13,383,000,000 |
| Return On Equity | 0.1968 | 0.5111 | 0.2336 |
| One Year Beta | -0.047 | 0.3313 | 0.3067 |
| Three Year Beta | 0.2452 | 0.3253 | 0.5445 |
| Five Year Beta | 0.4845 | 0.5251 | 0.5676 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Woods Eugene A. | Director | 2025-09-09 | 210 | A | 4,841 |
| Pinto Daniel E | Director | 2025-09-09 | 175 | A | 175 |
| HEWSON MARILLYN A | Director | 2025-09-09 | 280 | A | 13,816 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 2025-09-04 | 56,471 | A | 234,484 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 2025-09-04 | 56,471 | D | 178,013 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H Tuberville | Senator | 2024-11-15 | Sale (Full) | 2024-10-29 | Joint | $15,001 - $50,000 |
| Sheldon Whitehouse | Senator | 2024-08-21 | Sale (Full) | 2024-07-03 | Spouse | $15,001 - $50,000 |
| Sheldon Whitehouse | Senator | 2024-08-21 | Sale (Full) | 2024-07-03 | Self | $15,001 - $50,000 |
| Jerry Moran | Senator | 2024-01-17 | Sale (Full) | 2023-12-14 | Spouse | $1,001 - $15,000 |
| Jerry Moran | Senator | 2024-01-17 | Sale (Full) | 2023-12-14 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
| Sheri Biggs | 2025-10-05 | SC03 | Sale | 2025-03-19 | Spouse | $15,001 - $50,000 |
| Richard Dean Dr McCormick | 2025-09-17 | GA06 | Purchase | 2023-03-15 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-09-12 | MI09 | Purchase | 2025-08-04 | Spouse | $1,001 - $15,000 |
| Valerie Hoyle | 2025-09-12 | OR04 | Purchase | 2024-10-29 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Bill Few Associates, Inc. | 2025-09-30 | 1,666,619 | 8,988 | 185.4271 |
| LOCKERMAN FINANCIAL GROUP, INC. | 2025-09-30 | 206,558 | 1,114 | 185.4201 |
| WILLNER & HELLER, LLC | 2025-09-30 | 249,269 | 1,344 | 185.468 |
| Carnegie Investment Counsel | 2025-09-30 | 26,054,381 | 140,515 | 185.4206 |
| AMI INVESTMENT MANAGEMENT INC | 2025-09-30 | 5,015,480 | 27,049 | 185.422 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| NORTH COUNTRY FUNDS | 2025-08-31 | The North Country Large Cap Equity Fund | NCEGX | 9,500 | 1,683,115 | 1.3186 |
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Enhanced Yield ETF | DUBS | 10,719 | 1,765,848.06 | 0.7385 |
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Upside ETF | UPSD | 4,754 | 783,173.96 | 0.9493 |
| ETF Series Solutions | 2025-07-31 | Aptus Drawdown Managed Equity ETF | ADME | 6,996 | 1,152,521.04 | 0.5114 |
| ETF Series Solutions | 2025-07-31 | Aptus Collared Investment Opportunity ETF | ACIO | 62,091 | 10,228,871.34 | 0.5083 |